Organovo Holdings and University of California, San Francisco, (UCSF) have entered a partnership to develop 3D Bioprinted Tissues for skeletal disease research.
The partnership is funded by Methuselah Foundation as a part of University 3D Bioprinter Programme and will include the costs of bioprinter and key aspects of project execution.
Thermo Fisher Scientific has entered a co-development agreement with West China Hospital of Sichuan University to further develop precision medicine research platforms, as well as improve technologies and expertise to provide a better patient care.
According to the agreement, both the partners will jointly develop advanced laboratories and build training centres to train people as pathologic diagnosticians and to perform standardised pathology quality control.
ImmunoGen has announced to raise gross proceeds of $100m through the private placement of convertible senior unsecured notes due on 1 July 2021, which will be subscribed to by qualified institutional buyers.
The company plans to use the funds for its clinical trial expenditures, manufacturing experimental therapies, research and development (R&D) expenses and other corporate purposes.
Center Labs plans to increase its working capital and improve its financial structure through the funds raised from private placement of its 50 million common stock shares.
The offering will be completed in two tranches, which includes the first comprising 30 million shares and the second comprising 20 million shares.
The company expects to raise gross proceeds of $96m through the placement.
Spark Therapeutics plans to raise gross of $157.5m through the public offering of its 3.5 million common stock shares.
J.P. Morgan Securities, Cowen and Company and RBC Capital Markets are acting as the book running managers, while Stifel, Nicolaus & Company and SunTrust Robinson Humphrey are acting as lead managers, and Wilmer Cutler Pickering Hale and Dorr LLP is acting as the legal advisor for the offering.
The company intends to use the raised funds to increase working capital, for general corporate purposes and for internal R&D expenses.
Image: Organovo Holdings and University of California, San Francisco, (UCSF) have partnered to develop 3D Bioprinted Tissues. Photo: Courtesy of Payton Chung.